Skip to main content

Alejandro Cruz Gual

Institutions of which they are part

Research technician
Kidney Physiopathology
Vall Hebron Institut de Recerca

Alejandro Cruz Gual

Institutions of which they are part

Research technician
Kidney Physiopathology
Vall Hebron Institut de Recerca

Projects

Interacción entre huésped-microbiota y defectos en la integridad de la mucosa intestinal implicados en el origen del daño glomerular en el síndrome nefrótico idiopático

IP: Cristina Martínez Martínez
Collaborators: Alejandro Cruz Gual, Alvaro Domingo Madrid Aris, Ana Maria Gonzalez Castro
Funding agency: Instituto de Salud Carlos III
Funding: 38585.07
Reference: PI21/00757
Duration: 01/01/2022 - 30/06/2026

Patologia Cel·lular

IP: Patologia Cel·lular
Collaborators: Gema Ariceta Iraola, Alejandro Cruz Gual, Gerard Cantero Recasens, David Lorente García, Marina Muñoz López, Mercedes López González, Hector Rios Duro, Patologia Cel·lular, Luis Augusto Castro Sáder, Gloria Mª Fraga Rodriguez, Julieta Torchia
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 01600
Duration: 01/01/2022 - 30/06/2025

Biología de sistemas para el descubrimiento de mecanismos fisiopatológicos y dianas rerapéuticas en la hipomagnesimia familiarr primaria con hipercalciuria y nefrocalcinosis.

IP: Gema Ariceta Iraola
Collaborators: Alejandro Cruz Gual, Marina Muñoz López, Mercedes López González
Funding agency: Instituto de Salud Carlos III
Funding: 171820
Reference: PI18/01107
Duration: 01/01/2019 - 30/06/2023

Related news

The event, held at the VHIR Main Building, marked more than a decade of collaboration between the Institute and the HIPOFAM association and included a co-creation session to identify challenges and needs among patients and professionals.

The Oliver Wrong Research Award, granted by the Dent Disease Foundation, will fund a project combining kidney organoids and artificial intelligence to identify potential treatments for this rare kidney disease.

The team has discovered that a protein called SEC22B acts as a phenotype modifier and could be used as a potential urinary marker of the disease.

Related professionals

Daniel Perez Martinez

Daniel Perez Martinez

Predoctoral researcher
Diabetes and Metabolism
Read more
Lidia Fuertes Rioja

Lidia Fuertes Rioja

Research technician
Diabetes and Metabolism
Read more
Lorena Usero Redrejo

Lorena Usero Redrejo

Postdoctoral researcher
Protein kinases in cancer research
Read more
Simonas Valiuska

Simonas Valiuska

Postdoctoral researcher
Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.